Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more

Biodistribution of mRNA Therapeutics Delivered via Lipid Nanoparticles for Cancer Immunotherapy

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Biodistribution of mRNA Therapeutics Delivered via Lipid Nanoparticles for Cancer Immunotherapy

CELL & GENE | RNA | BIOLOGICS

A robust bioanalytical strategy is necessary to quantify the in vivo biodistribution of mRNA therapeutics delivered via lipid nanoparticles (LNPs) for cancer immunotherapy applications. Our approach details methodologies for assessing on-target delivery to tumors and immune cells while profiling accumulation in non-target tissues. The objective is to generate a comprehensive, IND-enabling data package that characterizes the safety and efficacy profile of novel LNP formulations, supported by advanced qPCR, ddPCR, and histology services.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Frequently Asked Questions (FAQ)

How do you differentiate between the mRNA payload within the LNP and the resulting expressed protein in tissue samples?

A: We employ a multi-modal analytical approach. Quantitative PCR (qPCR) or droplet digital PCR (ddPCR) is used to quantify the mRNA payload itself, providing direct measurement of tissue delivery. To measure the functional outcome, we use techniques like immunohistochemistry (IHC) or ligand binding assays (e.g., ELISA) to detect and quantify the translated protein product within the same tissues.

What is the standard tissue panel for a non-target biodistribution study of an intravenously administered LNP therapeutic?

A: A comprehensive panel is analyzed to build a complete safety profile. This typically includes the liver, spleen, lungs, heart, kidneys, brain, lymph nodes, bone marrow, and the injection site. Additional tissues may be included based on the specific LNP chemistry or therapeutic target.

Can your bioanalytical assays support pooled LNP administration studies for high-throughput screening?

A: Yes. Our molecular platforms are well-suited for advanced screening paradigms. We can support methodologies like the barcoded mRNA approach (b-mRNA), which enables the simultaneous quantification of organ delivery for multiple LNP candidates from a single study cohort via deep sequencing, accelerating lead optimization.

What GxP standards are applied to preclinical biodistribution studies?

A: The bioanalytical component of our biodistribution studies is conducted within a GxP-compliant framework to ensure data integrity, reproducibility, and regulatory acceptance. While early discovery in-life phases may be non-GxP, all pivotal IND-enabling studies rely on validated assays and GxP-level data reporting.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

Optimizing LNP-mRNA Delivery for Immunotherapy

The therapeutic efficacy of LNP-delivered mRNA in oncology depends directly on its biodistribution profile. Successful delivery to target immune cells or the tumor microenvironment, while minimizing exposure to non-target tissues like the liver and spleen, is the primary objective. Achieving this requires a deep understanding of how LNP formulation parameters influence in vivo behavior.

Our >100,000 sq ft facility is equipped to support the complex logistics and analytical workflows required for these programs. The infrastructure is designed to de-risk development, contributing to a projected 18-24 month IND timeline for many of our sponsors’ programs.

Advanced Methodologies for LNP Characterization

Modern LNP development has moved beyond simple lipid compositions. As research demonstrates, combinatorial design incorporating novel components like siloxanes can significantly augment cellular uptake and endosomal escape for tissue-specific delivery (PMID: 39354147). Similarly, high-throughput screening platforms using barcoded mRNA allow for the rapid in vivo assessment of many LNP candidates in parallel, identifying lead formulations with optimal delivery characteristics (PMID: 31678653).

Franklin Biolabs provides the bioanalytical support necessary to capitalize on these innovations. Our methodologies generate quantitative data packages that characterize both the tissue-level concentration of the mRNA payload and its functional expression as a therapeutic protein.

  • Quantitative Biodistribution (qPCR/ddPCR): Precisely measures mRNA copy numbers per gram of tissue, defining the concentration in both target and non-target organs.

  • Protein Expression Analysis (Histology/IHC): Our histology team visualizes and quantifies the translated protein product in situ, confirming functional delivery at the cellular level.

  • Safety & Tolerability Assessment: We integrate biodistribution data with clinical pathology and histology evaluations to build a comprehensive safety profile for IND submission. Programs supported by our core scientific team have maintained a 100% IND success rate on studies initiated since 2019. This legacy of success continues with the Franklin Biolabs brand, launched in 2024.

A close-up of a gloved hand handling PCR tubes with blue liquid in a laboratory rack, with a blue color overlay.

Commitment to Animal Welfare

All in vivo studies are conducted in strict accordance with our Animal Welfare policies, which incorporate the 3Rs principles of Replacement, Reduction, and Refinement. Our programs are overseen by AAALAC and USDA-accredited bodies, ensuring the highest ethical standards for all research activities.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities